GNI Group Ltd (2160)

Currency in JPY
2,983.0
+98.0(+3.40%)
Closed·
2160 Scorecard
Full Analysis
Prominent player in the Biotechnology industry
2160 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2,905.03,160.0
52 wk Range
1,469.04,410.0
Key Statistics
Bid/Ask
2,983.00 / 2,985.00
Prev. Close
2,885
Open
3,105
Day's Range
2,905-3,160
52 wk Range
1,469-4,410
Volume
3M
Average Volume (3m)
2.23M
1-Year Change
61.24%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2160 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4,300.0
Upside
+44.15%
Members' Sentiments
Bearish
Bullish
ProTips
High return over the last year

GNI Group Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

GNI Group Ltd Company Profile

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.

Employees
867
Market
Japan

Compare 2160 to Peers and Sector

Metrics to compare
2160
Peers
Sector
Relationship
P/E Ratio
−618.7x−6.0x−0.5x
PEG Ratio
5.950.010.00
Price/Book
4.7x5.4x2.6x
Price / LTM Sales
6.9x42.0x3.3x
Upside (Analyst Target)
44.2%74.4%40.1%
Fair Value Upside
Unlock9.7%5.1%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 4,300.0
(+44.15% Upside)

Earnings

Latest Release
Aug 14, 2025
EPS / Forecast
-7.62 / 121.61
Revenue / Forecast
6.93B / 5.43B
EPS Revisions
Last 90 days

2160 Income Statement

People Also Watch

7,200.0
7453
+0.70%
10,095.0
7012
-1.56%
6,243.0
4519
+1.83%
3,299.0
4676
+0.24%
8,149.0
8136
+2.04%

FAQ

What Stock Exchange Does GNI Trade On?

GNI is listed and trades on the Tokyo Stock Exchange stock exchange.

What Is the Stock Symbol for GNI?

The stock symbol for GNI is "2160."

What Is the GNI Market Cap?

As of today, GNI market cap is 165.71B.

What Is GNI's Earnings Per Share (TTM)?

The GNI EPS (TTM) is -5.33.

When Is the Next GNI Earnings Date?

GNI will release its next earnings report on 16 Nov 2025.

From a Technical Analysis Perspective, Is 2160 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has GNI Stock Split?

GNI has split 2 times.

How Many Employees Does GNI Have?

GNI has 867 employees.

What is the current trading status of GNI (2160)?

As of 17 Aug 2025, GNI (2160) is trading at a price of 2,983.00, with a previous close of 2,885.00. The stock has fluctuated within a day range of 2,905.00 to 3,160.00, while its 52-week range spans from 1,469.00 to 4,410.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.